Top

Published in:

01-03-2012 | Epidemiology (J Gelfand, Section Editor)

The Epidemiology and Prevention of Herpes Zoster

Authors: Harriet J. Forbes, Sara L. Thomas, Sinéad M. Langan

Published in: Current Dermatology Reports | Issue 1/2012

Abstract

Herpes zoster is a common disease among older individuals, affecting approximately 25% of people in their lifetime and resulting in appreciable morbidity. The risk of zoster increases sharply with age and immunosuppression, yet relatively little is known about other risk factors for zoster. A vaccine for zoster is now available that holds the potential to reduce incidence of zoster and its complications. In this review, the recent literature on zoster incidence and potential risk factors for the disease are summarized. Current methods of preventing zoster and its associated morbidity are discussed, including zoster vaccine and the use of antivirals.

• Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26–33. This is a comprehensive review of the incidence and risk factors for zoster.PubMedCrossRef

Gnann Jr JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340–6.PubMedCrossRef

Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38–47.PubMedCrossRef

Dworkin RH, Carrington D, Cunningham A, Kost RG, Levin MJ, McKendrick MW, et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antivir Res. 1997;33(2):73–85.PubMedCrossRef

Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.PubMedCrossRef

Kang J-H, Sheu J-J, Lin H-C. Increased risk of Guillain-Barre Syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis. 2010;51(5):525–30.PubMedCrossRef

Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342(9):635–45.PubMedCrossRef

Lin H-C, Chien C-W, Ho J-D. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology. 2010;74(10):792–7.PubMedCrossRef

Kang J-H, Ho J-D, Chen Y-H, Lin H-C. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke. 2009;40(11):3443–8.PubMedCrossRef

10.

Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.PubMedCrossRef

11.

Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. [Erratum appears in Mayo Clin Proc. 2008 Feb;83(2):255]. Mayo Clin Proc. 2007;82(11):1341–9.PubMedCrossRef

12.

Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al. Herpes zoster: burden of disease in France. Vaccine. 2010;28(50):7933–8.PubMedCrossRef

13.

Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.PubMedCrossRef

14.

Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.PubMedCrossRef

15.

Morens DM, Bregman DJ, West CM, Greene MH, Mazur MH, Dolin R, et al. An outbreak of varicella-zoster virus-infection among cancer-patients. Ann Intern Med. 1980;93(3):414–9.PubMed

16.

Melbye M, Grossman RJ, Goedert JJ, Eyster ME, Biggar RJ. Risk of aids after Herpes-Zoster. Lancet. 1987;1(8535):728–31.PubMedCrossRef

17.

Pergam SA, Forsberg CW, Boeckh MJ, Maynard C, Limaye AP, Wald A, et al. Herpes Zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13(1):15–23.PubMedCrossRef

18.

Buchbinder SP, Katz MH, Hessol NA, Liu JY, Omalley PM, Underwood R, et al. Herpes-Zoster and human-immunodeficiency-virus infection. J Infect Dis. 1992;166(5):1153–6.PubMedCrossRef

19.

Morgan D, Mahe C, Malamba S, Okongo M, Mayanja B, Whitworth J. Herpes zoster and HIV-1 infection in a rural Ugandan cohort. AIDS. 2001;15(2):223–9.PubMedCrossRef

20.

Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. Jaids-J Acq Imm Def. 2005;40(2):169–74.CrossRef

21.

Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2011.

22.

Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, Rosello R, Hernandez MV, Gomez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69(10):1751–5.PubMedCrossRef

23.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Jama. 2009;301(7):737–44.PubMedCrossRef

24.

Serac G, Tubach F, Mariette X, Salmon-Ceron D, Ravaud P, Liote F, et al. Risk of Herpes Zoster in Patients Receiving Anti-TNF-alpha in the Prospective French RATIO Registry. J Invest Dermatol. 2011.

25.

Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370–5.CrossRef

26.

Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431–8.PubMedCrossRef

27.

Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86(2):88–93.PubMedCrossRef

28.

Volpi A, Gatti A, Pica F. Frequency of herpes zoster recurrence. Mayo Clin Proc. 2011;86(6):586. author reply −7.PubMedCrossRef

29.

Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9–20.PubMed

30.

Goldman GS. The case against universal varicella vaccination. Int J Toxicol. 2006;25(5):313–7.PubMedCrossRef

31.

Leung J, Harpaz R, Molinari N-A, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52(3):332–40.PubMedCrossRef

32.

Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis. 2005;191(12):2002–7.PubMedCrossRef

33.

Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Publ Health. 2005;5:68.CrossRef

34.

Rimland D, Moanna A. Increasing incidence of herpes zoster among Veterans. Clin Infect Dis. 2010;50(7):1000–5.PubMedCrossRef

35.

Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect. 2007;135(6):908–13.PubMedCrossRef

36.

Perez-Farinos N, Ordobas M, Garcia-Fernandez C, Garcia-Comas L, Canellas S, Rodero I, et al. Varicella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997–2004. BMC Infect Dis. 2007;7:59.PubMedCrossRef

37.

Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine. 2010;28(13):2532–8.PubMedCrossRef

38.

Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578–85.PubMedCrossRef

39.

Tyndall MW, Nasio J, Agoki E, Malisa W, Ronald AR, Ndinyaachola JO, et al. Herpes-Zoster as the initial presentation of human-immunodeficiency-virus Type-I Infection in Kenya. Clin Infect Dis. 1995;21(4):1035–7.PubMedCrossRef

40.

Dehne KL, Dhlakama DG, Richter C, Mawadza M, Mcclean D, Huss R. Herpes-Zoster as an indicator of Hiv-infection in Africa. Trop Doct. 1992;22(2):68–70.PubMed

41.

Gonzaga HF, Jorge MA, Gonzaga LH, Barbosa CA, Chaves MD. Systemic and oral alterations in Brazilian patients with cutaneous herpes zoster. Braz Dent J. 2002;13(1):49–52.PubMed

42.

Mayanja B, Morgan D, Ross A, Whitworth J. The burden of mucocutaneous conditions and the association with HIV-1 infection in a rural community in Uganda. Trop Med Int Health. 1999;4(5):349–54.PubMedCrossRef

43.

Sokal JE, Firat D. Varicella-Zoster infection in Hodgkin’s disease: clinical and epidemiological aspects. Am J Med. 1965;39:452–63.PubMedCrossRef

44.

Schimpff S, Serpick A, Stoler B, Rumack B, Mellin H, Joseph JM, et al. Varicella-Zoster infection in patients with cancer. Ann Intern Med. 1972;76(2):241–54.PubMed

45.

Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis. 1990;49(8):630–3.PubMedCrossRef

46.

Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005;118(12):1416.PubMedCrossRef

47.

Cupps TR, Silverman GJ, Fauci AS. Herpes zoster in patients with treated Wegener’s granulomatosis. A possible role for cyclophosphamide. Am J Med. 1980;69(6):881–5.PubMedCrossRef

48.

Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 2011.

49.

Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008;36(3):226–30.PubMedCrossRef

50.

Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. Cmaj. 2011;183(5):E275–80.PubMedCrossRef

51.

Wilson JB. Thirty one years of herpes zoster in a rural practice. Br Med J (Clin Res Ed). 1986;293(6558):1349–51.CrossRef

52.

Thomas SL, Wheeler JG, Hall AJ. Micronutrient intake and the risk of herpes zoster: a case–control study. Int J Epidemiol. 2006;35(2):307–14.PubMedCrossRef

53.

Moszczynski P, Zabinski Z, Moszczynski Jr P, Rutowski J, Slowinski S, Tabarowski Z. Immunological findings in cigarette smokers. Toxicol Lett. 2001;118(3):121–7.PubMedCrossRef

54.

Cook RT. Alcohol abuse, alcoholism, and damage to the immune system–a review. Alcohol Clin Exp Res. 1998;22(9):1927–42.PubMed

55.

Schmader K, George LK, Burchett BM, Hamilton JD, Pieper CF. Race and stress in the incidence of herpes zoster in older adults. J Am Geriatr Soc. 1998;46(8):973–7.PubMed

56.

Kusnecov AW, Rabin BS. Stressor-induced alterations of immune function: mechanisms and issues. Int Arch Allergy Immunol. 1994;105(2):107–21.PubMedCrossRef

57.

Schmader K, Studenski S, Macmillan J, Grufferman S, Cohen HJ. Are stressful life events risk-factors for Herpes-Zoster. J Am Geriatr Soc. 1990;38(11):1188–94.PubMed

58.

Yang YW, Chen YH, Lin HW. Risk of herpes zoster among patients with psychiatric diseases: a population-based study. J Eur Acad Dermatol Venereol. 2011;25(4):447–53.PubMedCrossRef

59.

Baba K, Yabuuchi H, Takahashi M, Ogra PL. Increased incidence of herpes zoster in normal children infected with varicella zoster virus during infancy: community-based follow-up study. J Pediatr. 1986;108(3):372–7.PubMedCrossRef

60.

Donahue JG, Kieke BA, Gargiullo PM, Jumaan AO, Berger NR, McCauley JS, et al. Herpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination. Am J Public Health. 2010;100(6):1116–22.PubMedCrossRef

61.

Cho JW, Shin DH, Lee KS. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. J Dermatol Sci. 2007;45(3):213–5.PubMedCrossRef

62.

Haanpaa M, Nurmikko T, Hurme M. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis. 2002;34(2):112–4.PubMedCrossRef

63.

Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, et al. The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. Pain. 2004;110(1–2):329–36.PubMedCrossRef

64.

Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case–control study. Arch Dermatol. 2008;144(5):603–8.PubMedCrossRef

65.

Gatti A, Pica F, Boccia MTY, De Antoni F, Sabato AF, Volpi A. No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia. J Med Virol. 2010;82(6):1007–11.PubMedCrossRef

66.

Thomas SL, Wheeler JG, Hall AJ. Case–control study of the effect of mechanical trauma on the risk of herpes zoster. BMJ. 2004;328(7437):439.PubMedCrossRef

67.

Arndt V, Vine MF, Weigle K. Environmental chemical exposures and risk of herpes zoster. Environ Health Perspect. 1999;107(10):835–41.PubMedCrossRef

68.

• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84. This article describes the randomised control trial which demonstrated the efficacy of zoster vaccine in preventing zoster and PHN.PubMedCrossRef

69.

• Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Jama. 2011;305(2):160–6. This article describes a large retrospective cohort study that demonstrated zoster vaccine was effective in reducing zoster and PHN.PubMedCrossRef

70.

Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health. 2008;99(5):383–6.PubMed

71.

Prevention CfDCa. Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2008.

72.

Zhang JE, Delzell ES, Xie FL, Baddley JW, Spettell C, McMahan RM, et al. The use, safety and effectiveness of Herpes Zoster vaccination in individuals with inflammatory and autoimmune diseases. Pharmacoepidem Dr S. 2011;20:S363–4.

73.

American College of Rheumatology. Shingles vaccine doesn’t increase short term shingles risk in people taking biologics for autoimmune and inflammatory diseases. Press Release. 2011. http://www.rheumatology.org/about/newsroom/2011/2011_ASM_10_shingles_vaccine.asp. Accessed 1st December 2011.

74.

JCVI. Joint Committee on Vaccination and Immunisation Statement on varicella and herpes zoster vaccines. 2010.

75.

Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010;152(9):545–54.PubMed

76.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum. 2008;4(3):238–45.

77.

Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60:1528.

78.

Lu P-j, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1–6.PubMedCrossRef

79.

JS S, GL E. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008

80.

Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, et al. Barriers to the use of Herpes Zoster vaccine. Ann Intern Med. 2010;152(9):555.PubMed

81.

MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, et al. Concomitant administration of zoster and pneumococcal vaccines in adults >/=60 years old. Hum Vaccin. 2010;6(11):894–902.PubMedCrossRef

82.

Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32.PubMedCrossRef

83.

Li QF, Chen N, Yang J, Zhou MK, Zhou D, Zhang QW, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Db Syst Rev. 2009(2).

84.

Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22(2):341–7.PubMedCrossRef

85.

Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995;123(2):89–96.PubMed

86.

Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood. 2006;107(5):1800–5.PubMedCrossRef

Title: The Epidemiology and Prevention of Herpes Zoster
Authors: Harriet J. Forbes
Sara L. Thomas
Sinéad M. Langan
Publication date: 01-03-2012
Publisher: Current Science Inc.
Published in: Current Dermatology Reports / Issue 1/2012
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-011-0004-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Epidemiology and Prevention of Herpes Zoster

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Impact of Long-Term Antibiotic Use for Acne on Bacterial Ecology and Health Outcomes: A Review of Observational Studies

Epidemiology of Cosmetic Procedures: An Update for Dermatologists

Current Developments in Viral Skin Diseases

Comorbidity in Atopic Dermatitis

A Review of the Epidemiology of Cardiovascular Comorbidities in Psoriasis